From Financial Modeling Prep: 2025-03-06 16:00:06

SOPH’s ROIC is -52.00%, falling short of its 8.38% WACC. Peers like Rapid Micro Biosystems and Singular Genomics Systems face similar challenges with negative ROIC against their WACC. In contrast, Absci Corporation shows the highest ROIC to WACC ratio among competitors, suggesting better capital efficiency. Capital efficiency is crucial for long-term growth and stability in the healthcare technology sector.



Read more at Financial Modeling Prep:: SOPHiA GENETICS SA (NASDAQ:SOPH) Financial Analysi…